2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2717 Association of Medicaid expansion with overall survival in mycosis fungoides and Sézary syndrome: A national cancer database difference-in-differences analysis

Diego Alonso Olavarria-Bernal, MD, Henry Idrobo Quintero, MD2, Qianqian Liu, PhD3, Joel Michalek, PhD4, Sergio Hernandez Llamas, MD5, Adolfo Diaz Duque, MD, MSc6
1 UT Health San Antonio, San Antonio, Texas, United States
2 Clinica Central del Eje / Universidad Tecnologica de Pereira, Pereira, Colombia
3 UT Health San Antonio, San Antonio, Texas, United States
4 UT Health San Antonio, San Antonio, Texas, United States
5 UT Health San Antonio, San Antonio, Texas, United States
6 UT Health San Antonio, San Antonio, Texas, United States

Background

Mycosis fungoides (MF) and Sezary syndrome (SS) are rare cutaneous T-cell lymphomas characterized by prolonged disease courses requiring continuous access to specialized multidisciplinary care, skin-directed therapies, systemic treatments, and longitudinal follow-up. Because management frequently depends on sequential therapies delivered over many years, insurance coverage may substantially influence outcomes. We evaluated whether Medicaid expansion under the Affordable Care Act (ACA) was associated with improved overall survival (OS) among patients with MF/SS using a national Difference-in-Differences (DiD) framework.

 Methods

Adults aged ≥40 years diagnosed with MF/SS between 2004 and 2023 were identified from the National Cancer Database. States were classified according to Medicaid expansion status, and patients were stratified into pre-expansion (2004–2013) and post-expansion (2014–2023) cohorts. Demographic, socioeconomic, facility, and clinical characteristics were compared between groups. Difference-in-Differences methodology was used to evaluate the association between Medicaid expansion and survival while accounting for secular improvements over time. Overall survival was analyzed using multivariable-adjusted Cox proportional hazards models with adjusted survival curves.

Results

A total of 13,866 patients with MF/SS were identified, including 5,086 diagnosed before 2014 and 8,780 diagnosed after 2014. Before ACA implementation, 4,001 (79%) patients resided in Medicaid expansion states and 1,085 (21%) in non-expansion states. After 2014, 6,292 (79%) resided in expansion states and 1,690 (21%) in non-expansion states.

Compared with patients diagnosed before 2014, those diagnosed after ACA implementation were older (median 65 vs. 63 years, P<0.001), while sex distribution remained similar (42% vs. 43% female, P=0.20). Hispanic representation increased (6.8% vs. 4.7%, P<0.001), and a greater proportion of patients resided in metropolitan areas (83% vs. 79%, P<0.001). Patients diagnosed after 2014 also more frequently lived in higher-income communities, with residence in neighborhoods having annual median household income ≥$74,063 increasing from 36% to 38% (P<0.001).

Treatment patterns remained highly centralized, with approximately 86% of patients receiving care at academic cancer programs in both eras (P>0.9). Insurance coverage changed substantially following ACA implementation. Government-sponsored insurance increased from 45% to 54%, private insurance decreased from 46% to 43%, and the proportion of uninsured patients declined from 3.3% to 1.7% (P<0.001).

Disease stage at diagnosis remained largely stable, with stage I disease representing approximately 61% of cases in both periods, while stage IV disease increased modestly (6.9% vs. 8.7%). Despite this, comorbidity burden increased significantly over time, with Charlson-Deyo scores ≥2 rising from 2.4% to 5.0% (P<0.001), reflecting a progressively older and more medically complex patient population.

Adjusted survival analyses demonstrated no significant difference in OS between Medicaid expansion and non-expansion states before ACA implementation (P=0.26). In contrast, after Medicaid expansion, patients residing in expansion states experienced significantly improved adjusted overall survival compared with those residing in non-expansion states (P<0.0001). Adjusted survival curves demonstrated early and persistent separation throughout follow-up, with widening divergence over time despite increasing comorbidity burden in the contemporary cohort.

Conclusions

Among adults with MF/SS, Medicaid expansion was associated with significantly improved adjusted overall survival following ACA implementation, whereas no survival difference was observed before expansion. Given the chronic nature of MF/SS and the dependence on prolonged multidisciplinary management and sequential systemic therapies, these findings suggest that expanded insurance coverage may have improved continuity of specialty care and access to modern treatments, translating into meaningful population-level survival gains. These data support healthcare policies that facilitate sustained access to specialized oncologic care for patients with rare cutaneous T-cell lymphomas.

Diego Alonso Olavarria-Bernal, MD: No relevant conflicts of interest to declare.